In the absence of a clear imaging rationale for Bcr-Abl targeting in CML, and a potentially limited applicability to c-Kit-positive gastrointestinal stromal tumor (GIST), for which imatinib is also approved for therapy, none of these radioligands were clinically validated. This evidence concerns the gene KIT and gastrointestinal stromal tumor.